Navigation Links
Xlumena Closes Series C Financing; Focuses on Expanding Global Commercial Presence and Obtaining FDA Clearance

MOUNTAIN VIEW, Calif., Dec. 3, 2013 /PRNewswire/ -- Xlumena, Inc., a leader in the development of advanced endoscopic devices, today announced the close of a $25 million Series C financing.  Led by Third Point LLC, the round of funding includes existing investors Prism VentureWorks, Charter Life Sciences, Ascent Biomedical Ventures and Aperture Venture Partners.  Xlumena will use the Series C proceeds to expand global commercialization efforts for its AXIOS family of devices and continue the process of bringing this innovative platform to the US interventional endoscopy community. 

Xlumena's principal product, the AXIOS Stent and Delivery System, obtained a CE mark designation in Europe in 2012 and is available in a select number of centers.  The AXIOS Stent, a fully-covered, dual-flanged stent, is delivered under endoscopic ultrasound guidance and designed to create a secure drainage pathway between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst.  The HOT AXIOS, also available in Europe, incorporates cautery into the delivery system, enabling access and stent delivery in a single device.  The AXIOS devices have been used in the treatment of acute cholecystitis, biliary inflammation associated with strictures or stones in the bile duct, and pancreatic pseudocysts.

Greg Patterson, President and CEO of Xlumena, commented: "As a company, we have always focused on the needs of interventional endoscopists. This financing will allow us to better meet the global commercial demand and provide a springboard for an initial launch of the AXIOS in the United States once FDA clearance is granted. We look forward to this new collaboration with Third Point and a continued partnership with our existing investors."  Jason Hong Ph.D. will represent Third Point LLC on the Xlumena Board of Directors. 

For more information about the AXIOS Stent and Delivery System, please visit

About Xlumena, Inc.: Xlumena is the leader in developing products that enable advanced image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach. 

About Third Point: Third Point LLC is an SEC-registered investment adviser headquartered in New York. Founded in 1995, Third Point follows an event-driven approach to global investing.

CAUTION: The AXIOS and HOT AXIOS devices have CE mark designation in Europe. They are not available for sale in the United States. 

SOURCE Xlumena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tyber Medical Closes Private Placement Funding Round
2. Catabasis Closes $32.4 Million Series B Financing
3. CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings
4. TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. MEDTEC China 2013: Conference Program Closes in on Finalization
7. Drip Drop Inc. closes $3.0M Series A-1 round with investments from John Elway, Ronnie Lott, and Sam Nazarian.
8. Acutus Medical Closes Series B Funding at $28 Million
9. Organovo Holdings, Inc. Closes $46.6 Million Public Offering of Common Stock and Exercise of Over-Allotment Option
10. Endexx closes Acquisition of Dispense Labs LLC.
11. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
Post Your Comments:
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Allergan plc ... an agreement with the New York State ... 2 of the Sherman Act, and other statutes with the ... in February 2014, to cease marketing and selling the now ... of settlement, Allergan admits no liability, has released its counterclaims ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... water accessible for all, Water For Empowerment ™ attracts volunteers together who ... clean water by empowering women as key stakeholders in the process. The non-profit ...
Breaking Medicine News(10 mins):